ImmunoGen, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q3 2023.

Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
02 Nov 2023

Quick Takeaways

  • ImmunoGen, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q3 2023.
  • Headline metric: Return On Equity -20%.

What Changed

  • Return On Equity YoY change: <span class="text-red-600">-87%</span>.
  • Most recent SEC facts end date: 25 Oct 2023.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2023-10-25) highlights Return On Equity -19.9%, Return On Assets -12.5%, and Current Ratio 5.7x.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

37.5/100

Weak Confidence medium

Return On Equity

-20%

Metric score 0.0/100

Return On Assets

-12%

Metric score 0.0/100

Financial Health

Current Ratio
5.7x
Quick Ratio
5.65x
Debt to Equity
0.63x

Strengths

Debt-to-equity and NetIncomeLoss YoY

Watchpoints

Return On Equity, Return On Assets, and Current Ratio

Key metrics snapshot

Return On Equity

-20%

YoY: -87%

Industry median: -43% (n=675)

View history

Return On Assets

-12%

YoY: -80%

Industry median: -47% (n=673)

View history

Current Ratio

5.7x

YoY: +79%

Industry median: 3.39x (n=667)

View history

Quick Ratio

5.65x

YoY: +77%

Industry median: 1.51x (n=289)

View history

Debt-to-equity

0.63x

YoY: -7.8%

Industry median: 0.26x (n=530)

View history

NetIncomeLoss YoY

63%

YoY:

Industry median: -0.93% (n=641)

View history

Profitability

Metric Latest value YoY change
Return On Equity -20% -87%
Return On Assets -12% -80%

Financial Health

Metric Latest value YoY change
Current Ratio 5.7x +79%
Quick Ratio 5.65x +77%
Debt-to-equity 0.63x -7.8%

Growth

Metric Latest value YoY change
NetIncomeLoss YoY 63%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 266,264,274 +21%
Common Stock, Shares, Outstanding 265,842,000 +20%
Common Stock, Value, Issued $2,435,000 +10%
Weighted Average Number of Shares Outstanding, Basic 273,341,000 +7.8%
Weighted Average Number of Shares Outstanding, Diluted 287,590,000 +13%

Additional Metrics

Metric Latest value YoY change
Research and Development Expense $207,752,000 +1.9%
Operating Income (Loss) $80,185,000 +59%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $29,582,000
Income Tax Expense (Benefit) $1,166,000
Earnings Per Share, Basic 0 +63%
Earnings Per Share, Diluted 0.1
Cash and Cash Equivalents, at Carrying Value $605,535,000 +96%
Inventory, Net $5,495,000
Assets, Current $766,900,000 +132%
Property, Plant and Equipment, Net $4,431,000 -0.96%
Operating Lease, Right-of-Use Asset $8,338,000 -23%
Other Assets, Noncurrent $14,159,000 +8.1%
Assets $822,101,000 +129%
Accounts Payable, Current $24,853,000 +23%
Employee-related Liabilities, Current $15,155,000 +76%
Contract with Customer, Liability, Current $37,186,000 +147%
Liabilities, Current $134,660,000 +30%
Contract with Customer, Liability, Noncurrent $26,718,000 -31%
Operating Lease, Liability, Noncurrent $7,759,000 -36%
Other Liabilities, Noncurrent $2,800,000 +833%
Liabilities $260,505,000 +44%
Retained Earnings (Accumulated Deficit) $1,708,586,000 -4.5%
Stockholders' Equity Attributable to Parent $561,596,000 +215%
Liabilities and Equity $822,101,000 +129%
Common Stock, Shares Authorized 600,000,000 0%
Common Stock, Shares, Issued 265,842,000 +20%
Common Stock, Par or Stated Value Per Share 0.01 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $605,535,000 +96%
Operating Lease, Liability, Current $4,458,000 +12%
Preferred Stock, Shares Issued 22,000
Preferred Stock, Shares Authorized 5,000,000 0%
Preferred Stock, Shares Outstanding 22,000
Preferred Stock, Par or Stated Value Per Share 0.01 0%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY